Literature DB >> 23135359

Endocrine gland-derived vascular endothelial growth factor strengthens cell invasion ability via prokineticin receptor 2 in colon cancer cell lines.

Shinsuke Tabata1, Takanori Goi, Toshiyuki Nakazawa, Youhei Kimura, Kanji Katayama, Akio Yamaguchi.   

Abstract

Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) has recently been identified as one of the vascular endothelial growth factors, and it is considered that the overexpression of EG-VEGF in colon cancer is related to hepatic metastasis. In this study, we report our recent novel findings of the involvement of EG-VEGF in cell invasion of colon cancer cells. Colon cancer cell lines (DLD-1 and HCT116) with high expression of prokineticin receptor (PK-R) 1 and 2 were stimulated with the EG-VEGF protein. Furthermore, Matrigel cell invasion assay was performed to examine the changes in cancer cell invasion. In addition, we investigated the mRNA expression of matrix metalloproteinase (MMP)-2, -7 and -9 in cancer cells. Finally, the EG-VEGF receptor on the colon cancer cell membrane was blocked by anti-PK-R1 and -PK-R2 antibodies to study whether cell invasion ability would be altered. In colon cancer cell lines where the expression of PK-R1 and 2 was confirmed, stimulation with EG-VEGF increased cell invasion a maximum of ~3-5 times. Furthermore, an increase in the mRNA and protein expression of MMP-2, -7 and -9 was observed. We also observed that the cell invasion rate decreased only after exposure to the anti-PK-R2 antibody. The study showed that the EG-VEGF protein may act on MMP-2, -7 and -9 via PK-R2 to strengthen cell invasion ability in colon cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23135359     DOI: 10.3892/or.2012.2124

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  The anti-tumor effect is enhanced by simultaneously targeting VEGF and PROK1 in colorectal cancer.

Authors:  Takanori Goi; Toshiyuki Nakazawa; Yasuo Hirono; Akio Yamaguchi
Journal:  Oncotarget       Date:  2015-03-20

2.  Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors.

Authors:  Dorothee Heck; Sebastian Wortmann; Luitgard Kraus; Cristina L Ronchi; Richard O Sinnott; Martin Fassnacht; Silviu Sbiera
Journal:  Horm Cancer       Date:  2015-12       Impact factor: 3.869

3.  Expression of prokineticin-receptor2(PK-R2) is a new prognostic factor in human colorectal cancer.

Authors:  Takanori Goi; Hidetaka Kurebayashi; Yuki Ueda; Takayuki Naruse; Toshiyuki Nakazawa; Kenji Koneri; Yasuo Hirono; Kanji Katayama; Akio Yamaguchi
Journal:  Oncotarget       Date:  2015-10-13

4.  The prognosis was poorer in colorectal cancers that expressed both VEGF and PROK1 (No correlation coefficient between VEGF and PROK1).

Authors:  Takanori Goi; Toshiyuki Nakazawa; Yasuo Hirono; Akio Yamaguchi
Journal:  Oncotarget       Date:  2015-10-06

Review 5.  Endocrine Gland-Derived Vascular Endothelial Growth Factor/Prokineticin-1 in Cancer Development and Tumor Angiogenesis.

Authors:  Ana Silvia Corlan; Anca Maria Cîmpean; Adriana-Andreea Jitariu; Eugen Melnic; Marius Raica
Journal:  Int J Endocrinol       Date:  2017-03-12       Impact factor: 3.257

6.  Plasma Prokineticin 1, a prognostic biomarker in colorectal cancer patients with curative resection: a retrospective cohort study.

Authors:  Noriyuki Tagai; Takanori Goi; Michiaki Shimada; Hidetaka Kurebayashi
Journal:  World J Surg Oncol       Date:  2021-10-18       Impact factor: 2.754

7.  Knockdown of VEGFR2 inhibits proliferation and induces apoptosis in hemangioma-derived endothelial cells.

Authors:  J M Ou; Z Y Yu; M K Qiu; Y X Dai; Q Dong; J Shen; X F Wang; Y B Liu; Z W Quan; Z W Fei
Journal:  Eur J Histochem       Date:  2014-03-17       Impact factor: 3.188

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.